The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes

NCT ID: NCT02248714

Last Updated: 2019-07-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

131 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further realize the safety and effect of Glucerna SR on daily and day-to-day amplitude of blood glucose fluctuation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response. About 24% of the total energy provided by Glucerna SR is due to monounsaturated fatty acids, which can help keep good metabolic state in accordance with the recommendations of the American Heart Association. The aim of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further realize the safety and effect of Glucerna SR consumed as a meal replacement at breakfast meal on daily and day-to-day amplitude of blood glucose fluctuation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study arm

Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)

Group Type EXPERIMENTAL

Glucerna SR

Intervention Type DIETARY_SUPPLEMENT

Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.

Control arm

Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glucerna SR

Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed type 2 diabetes mellitus
* FPG≤13mmol/l and/or 2hPG≤18mmol/l
* HbA1c≥7.0%
* BMI (Body Mass Index)≥18.5kg/m2

Exclusion Criteria

* Patients taking any class of injectible or oral hypoglycemia agents to manage their hyperglycemia.
* Female patients are in gestation, lactation or intend to be pregnant in the study period.
* Patients are with type 1 diabetes, or other special types of diabetes, or gestational diabetes mellitus.
* Patients with drug hypersensitivity.
* Patients with obvious hepatic or renal diseases (ALT, T-Bil\>1.5 times of upper limit)
* Patients with severe or unstable angina, or heart failure (NYHA class III/IV)
* Patients having acute complications, or chronic complications maintained insulin therapy or insulin therapy under stress.
* Patients with chronic consumptive diseases like cerebrovascular disease, tumor, tuberculosis, or hematopathy, psychosis, autoimmune disease or severe digestive dysfunction.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuqian Bao

Director of the Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yuqian Bao, MD

Role: PRINCIPAL_INVESTIGATOR

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Shanghai, Shanghai Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-32

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Examining The Role of CGM in T2DM
NCT01614262 COMPLETED NA
The CGM-OGTT Glycemic Homeostasis Study
NCT07288372 NOT_YET_RECRUITING